Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Relay Therapeutics to Participate in Upcoming Investor Conferences By: Relay Therapeutics, Inc. via GlobeNewswire November 07, 2024 at 16:05 PM EST CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats: Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ETStifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ETJefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter. Contact:Megan Goulart617-545-5526 mgoulart@relaytx.com Media:Dan Budwick1AB973-271-6085dan@1abmedia.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Relay Therapeutics to Participate in Upcoming Investor Conferences By: Relay Therapeutics, Inc. via GlobeNewswire November 07, 2024 at 16:05 PM EST CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats: Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ETStifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ETJefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter. Contact:Megan Goulart617-545-5526 mgoulart@relaytx.com Media:Dan Budwick1AB973-271-6085dan@1abmedia.com
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats: Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ETStifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ETJefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter. Contact:Megan Goulart617-545-5526 mgoulart@relaytx.com Media:Dan Budwick1AB973-271-6085dan@1abmedia.com
